Bristol-Myers Squibb-Bristol Myers Squibb Transforms the Classical Hodgkin Lymphoma Treatment Paradigm with Expanded U.S. and EMA Approvals for Opdivo® (nivolumab)

Bristol Myers Squibb Transforms the Classical Hodgkin Lymphoma Treatment Paradigm with Expanded U.S. and EMA Approvals for Opdivo® (nivolumab)

百时美施贵宝(US:BMY) Businesswire·2026-03-21 04:42

公司新闻与产品进展 - 百时美施贵宝公司宣布其产品Opdivo®（纳武利尤单抗）获得美国食品药品监督管理局和欧洲药品管理局的扩展批准，用于治疗经典型霍奇金淋巴瘤 [1] - 公司将此进展定位为对经典型霍奇金淋巴瘤治疗范式的转变 [1] 行业与市场影响 - 此次监管批准涉及美国和欧洲两大关键药品市场，可能影响全球经典型霍奇金淋巴瘤的治疗标准与市场竞争格局 [1]

Bristol-Myers Squibb-Bristol Myers Squibb Transforms the Classical Hodgkin Lymphoma Treatment Paradigm with Expanded U.S. and EMA Approvals for Opdivo® (nivolumab) - Reportify